Antiarrhythmic Drug Initiation for Atrial Fibrillation in the USA: How and Where

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

Atrial fibrillation (AF) is common and occurs in approximately 8% of adults over 65 years of age in the United States. Prevention of AF, with maintenance of healthy weight, treatment of sleep apnea, and regular exercise are key strategies. As prevention is often inadequate, the role of antiarrhythmic drugs (AADs) is paramount. Adverse events are often uncovered in the first 24 h of initiation, and occur approximately 10%–15% of the time, but AADs can still be used safely [2]. Herein, we describe the various categories in a practical guide to initiation to make clinicians more comfortable with starting and maintaining antiarrhythmic therapy in both the inpatient and outpatient setting. The central illustration summarizes the article.

Cite

CITATION STYLE

APA

Newman, J., Strickberger, A., Spears, J., & Kowey, P. (2025, July 1). Antiarrhythmic Drug Initiation for Atrial Fibrillation in the USA: How and Where. Journal of Cardiovascular Electrophysiology. John Wiley and Sons Inc. https://doi.org/10.1111/jce.16681

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free